Tscan Therapeutics Inc (TCRX) - Total Assets
Based on the latest financial reports, Tscan Therapeutics Inc (TCRX) holds total assets worth $201.99 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Tscan Therapeutics Inc cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Tscan Therapeutics Inc - Total Assets Trend (2019–2025)
This chart illustrates how Tscan Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See Tscan Therapeutics Inc shareholders equity for net asset value and shareholders' equity analysis.
Tscan Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Tscan Therapeutics Inc's total assets of $201.99 Million consist of 66.6% current assets and 33.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 66.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Tscan Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Tscan Therapeutics Inc (TCRX) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tscan Therapeutics Inc's current assets represent 66.6% of total assets in 2025, a decrease from 85.8% in 2019.
- Cash Position: Cash and equivalents constituted 66.6% of total assets in 2025, down from 84.6% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Tscan Therapeutics Inc Competitors by Total Assets
Key competitors of Tscan Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Tscan Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.65 | 8.55 | 5.34 |
| Quick Ratio | 6.65 | 8.55 | 5.34 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $112.80 Million | $225.02 Million | $89.45 Million |
Tscan Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Tscan Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.60 |
| Latest Market Cap to Assets Ratio | 0.20 |
| Asset Growth Rate (YoY) | -38.4% |
| Total Assets | $228.79 Million |
| Market Capitalization | $45.38 Million USD |
Valuation Analysis
Below Book Valuation: The market values Tscan Therapeutics Inc's assets below their book value (0.20x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Tscan Therapeutics Inc's assets decreased by 38.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Tscan Therapeutics Inc (2019–2025)
The table below shows the annual total assets of Tscan Therapeutics Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $228.79 Million | -38.35% |
| 2024-12-31 | $371.12 Million | +36.37% |
| 2023-12-31 | $272.15 Million | +36.70% |
| 2022-12-31 | $199.09 Million | +5.84% |
| 2021-12-31 | $188.11 Million | +278.20% |
| 2020-12-31 | $49.74 Million | +0.72% |
| 2019-12-31 | $49.38 Million | -- |
About Tscan Therapeutics Inc
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic… Read more